哈药股份(600664.SH)：注射用头孢噻肟钠通过仿制药一致性评价

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) has received approval from the National Medical Products Administration for its injectable Cefoperazone Sodium, indicating a successful evaluation of the drug's quality and efficacy consistency as a generic medication [1]. Group 1 - The company’s subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, is the entity that received the approval for the injectable Cefoperazone Sodium [1]. - The approved formulations include 1.0g and 0.5g dosages, with specific notification numbers for each [1]. - Injectable Cefoperazone Sodium is indicated for various infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, gynecological infections, bacteremia/sepsis, skin and soft tissue infections, abdominal infections, bone and joint infections, and central nervous system infections [1].